(Press-News.org) Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac myosin inhibitors (CMIs) are being developed to help patients with hypertrophic obstructive cardiomyopathy (HOCM), a disease in which the heart muscle becomes thickened leading to reduced blood flow out of the heart. In a new analysis led by researchers from Mass General Brigham, investigators probed multiple exercise response patterns before and after exposure to the CMI aficamten in the SEQUIOA-HCM trial. Results are published today in JAMA Cardiology.
“My laboratory has had a longstanding focus on understanding mechanisms of exercise intolerance and exploration of therapeutic interventions to improve exercise capacity,” said corresponding author Gregory Lewis, MD. the Section Head of Heart Failure and Director of Cardiopulmonary Exercise Testing at Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system.
The phase-3, placebo-controlled, randomized clinical trial, SEQUIOA-HCM, sponsored by Cytokinetics, Inc., evaluated effects of aficamten on exercise capacity and cardiac function. The primary endpoint of the study was change in peak oxygen uptake as measured by cardiopulmonary exercise testing under the oversight of the MGH Cardiopulmonary Exercise Testing Core Laboratory directed by Lewis.
The study found marked improvements in both peak oxygen uptake as recently reported in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2401424). In addition, cardiac structure and function measures improved significantly, as adjudicated by the Echocardiography Core Laboratory directed by Scott Solomon, MD, from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system.
The team assessed 263 patients who completed exercise testing at the start of the trial and 24 weeks later. They saw significant improvements in several measurements, including workload achieved, breathing efficiency and cardiac power generated during exercise, and submaximum exercise capacity measured at the anaerobic threshold. In addition, they describe a novel measurement that combined submaximum and maximum exercise capacity as an integrated way to assess exercise capacity improvement. The investigators found that changes in exercise responses related to changes in cardiac structure and function beyond just outflow obstruction.
Their findings have important clinical implications for treating HOCM and could also be relevant to broader populations of non-obstructive hypertrophic cardiomyopath.
Authorship: In addition to Lewis, Mass General Brigham authors include Brian L. Claggett, Scott D. Solomon, Ian J. Kulac, and Isabela Landsteiner. Additional authors include Matthew M. Y. Lee, Ahmad Masri, Michael E. Nassif, Roberto Barriales-Villa, Theodore P. Abraham, Caroline J. Coats, Juan Ramón Gimeno, Changsheng Ma, Martin S. Maron,Iacopo Olivotto, Anjali T. Owens, Josef Veselka, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, AmyWohltman, for the SEQUOIA-HCM Investigators.
Disclosures: Lewis reported receiving grants from Cytokinetics, Amgen, Applied Therapeutics, Pfizer, AstraZeneca, Rivus, the National Institutes of Health, and Pharmacosmos, and consulting fees from Edwards and American Regent outside the submitted work. Claggett reported receiving consulting fees from Alnylam, Cardurion, Corvia, Cytokinetics, Intellia, Rocket, CVRX, and BMS outside the submitted work. Dr Solomon reported receiving grants from Cytokinetics, Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly, the National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, and US2.AI and consulting fees from Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo outside the submitted work. Additional disclosures can be found in the paper.
Funding: The SEQUOIA-HCM trial is funded by Cytokinetics, Incorporated.
Paper cited: Lee MY et al. “Aficamten and Cardiopulmonary Exercise Test Performance A Substudy of the SEQUOIA-HCM Randomized Clinical Trial” JAMA Cardiology DOI: 10.1001/jamacardio.2024.2781
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
Leuven/Amsterdam/Cambridge, 5 September– A team of researchers at the VIB-KU Leuven Center for Cancer Biology, the Netherlands Cancer Institute and Oncode Institute and the University of Cambridge have discovered that a defensive mechanism connected to the menstrual cycle plays a role in spreading mutant cells within mammary tissue. A new study published in Nature describes how the growth and subsequent removal of extra milk ducts in breast tissue during the menstrual cycle can contribute to the spread of mutant cells leading to large mutant fields prone to develop tumors.
Although tissue in healthy individuals may look completely normal, ...
New research shows how oceans can be used to help address major challenges such as the shortage of antimicrobial medicines, solutions for plastic pollution and novel enzymes for genome editing.
In the past 20 years, scientists have greatly increased the number of microbial genomes they have collected from the ocean. However, using this information for biotechnology and medicine has been difficult.
For this new study, led by BGI Research in China in collaboration with the Shandong University, Xiamen University, ...
Investigators involved in a multicenter study co-led by Cedars-Sinai discovered a pathway by which immune cells prevent the lungs’ protective barrier from healing after viral infections like COVID-19. The findings, published in Nature may lead to new therapeutic treatment options.
The COVID-19 pandemic revealed how viral infections can cause long-lasting effects—a condition called long COVID. Also known as post-acute sequelae of SARS-CoV-2, long COVID has left a devastating trail of people who continue to live with ...
Korea Electrotechnology Research Institute (KERI) has succeeded in domestically developing the ‘CNC driving system’ technology, a core component of machine tools—often referred to as "Mother Machines," the machines that make other machines.
The CNC (Computer Numerical Control) system is an electronic module that processes numerical information via a computer and automatically controls all functions of machine tools, including position, speed, and rotation of a machine tool. In a computer, it plays a role similar to that of a CPU.
A major challenge ...
Digital Science today announces the launch of Papers Pro, an AI-enhanced premium version of its acclaimed reference manager, Papers.
As part of the ReadCube suite of literature solutions, Papers Pro is designed to make researchers and students more productive in their daily tasks by integrating cutting-edge AI tools to transform how they discover, organize, read, annotate, share and cite research materials.
Search and discovery has always been a core part of the Papers workflow. The launch of Papers Pro introduces new search capabilities, powered by Dimensions, one of the world’s largest ...
Sept. 4, 2024
WASHINGTON, D.C. – The Patient-Centered Outcomes Research Institute (PCORI) today began inviting proposals through eight new funding opportunities, including three PCORI Funding Announcements (PFAs) for patient-centered comparative clinical effectiveness research (CER). One PFA is offering up to $100 million to support CER studies promoting healthy children and youth, a demographic representing more than a third of the U.S. population and facing a range of mental and physical health challenges.
“These ...
It turns out that a particular gene has a great influence on longevity, a new study from the University of Copenhagen concludes. This may pave the way for new treatment.
Sleep, fasting, exercise, green porridge, black coffee, a healthy social life …
There is an abundance of advice out there on how to live a good, long life. Researchers are working hard to determine why some people live longer than others, and how we get the most out of our increasingly long lives.
Now researchers from the Center for Healthy Aging, Department of Cellular and Molecular Medicine at the University of Copenhagen have made a breakthrough. They have discovered that ...
SAN ANTONIO — September 4, 2024 — Southwest Research Institute has signed a memorandum of understanding (MOU) with Blade Energy Partners, establishing a new research collaboration focused on advancing carbon dioxide storage technology to reduce greenhouse gas emissions.
Carbon capture, utilization, and storage (CCUS) refers to the practices of capturing CO2 from its industrial sources or the atmosphere, transport it using pipelines and other means, using it as alternative fuel or other industrial applications, and storing it for later use. The drive to meet net-zero greenhouse gas emissions goals and ...
A research paper by scientists at University of Coimbra proposed an integrated approach targeting the design and fabrication of pneumatic soft actuators in a single casting step. Molds and sacrificial water-soluble hollow cores are printed using fused filament fabrication.
The new research paper, published on Jul. 17 in the journal Cyborg and Bionic Systems, presented an integrated process for the design and fabrication of soft robot actuators in a single casting. The author proved the availability, versatility, and effectiveness of the proposed methods, contributing to accelerating the design and fabrication of soft robots.
Bio-inspired soft robots have already shown the ability to handle ...
Neuroendocrine tumors (NETs) of the gastrointestinal (GI) tract are a rare and heterogeneous group of malignancies arising from the neuroendocrine cell system. These tumors are more commonly encountered in the stomach, appendix, small bowel, rectum, and pancreas. Over the past few decades, the incidence of GI NETs has increased due to improved diagnostic capabilities and an aging population. The management of these tumors requires a careful assessment of various factors, including the site, size, grading, depth of invasion, and local lymphadenopathy, as they significantly impact prognosis and treatment ...
